News Releases

Date Title View
Toggle Summary Aerie Pharmaceuticals Establishes GMP PRINT® Production Facility in an Expanded Global Headquarters
The Company now occupies more than 60,000 sq. ft. of laboratory and office space at the Durham, North Carolina , facility DURHAM, N.C. --(BUSINESS WIRE)--Oct. 23, 2018-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and
View HTML
Toggle Summary Aerie Pharmaceuticals, Inc. Announces Drug Application for Regulatory Approval Accepted for Review in Europe
European Medicines Agency (EMA) will begin review of the Marketing Authorisation Application (MAA) for Rhokiinsa ® (netarsudil ophthalmic solution) 0.02%, currently marketed as Rhopressa ® in the United States DURHAM, N.C. --(BUSINESS WIRE)--Oct. 9, 2018-- Aerie Pharmaceuticals, Inc.
View HTML
Toggle Summary Aerie Pharmaceuticals to Present at the Cantor Fitzgerald 2018 Global Healthcare Conference
DURHAM, N.C. --(BUSINESS WIRE)--Sep. 25, 2018-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Appointment of Damien Monaghan, Quality Director
DURHAM, N.C. --(BUSINESS WIRE)--Sep. 24, 2018-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other
View HTML
Toggle Summary Aerie Pharmaceuticals to Present at Ophthalmology Futures Forums in Vienna, Austria
DURHAM, N.C. --(BUSINESS WIRE)--Sep. 13, 2018-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other
View HTML
Toggle Summary Aerie Pharmaceuticals Appoints David W. Gryska to the Company’s Board of Directors
DURHAM, N.C. --(BUSINESS WIRE)--Sep. 12, 2018-- Aerie Pharmaceuticals, Inc.  (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Appointment of Robert Finan as Director of Finance
DURHAM, N.C. --(BUSINESS WIRE)--Sep. 11, 2018-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Appointment of Thomas A. Shepard as Vice President, Implant Manufacturing
DURHAM, N.C. --(BUSINESS WIRE)--Sep. 10, 2018-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Appointment of Jeffrey White, Ph.D. as Director, Toxicology and Pharmacokinetics
DURHAM, N.C. --(BUSINESS WIRE)--Aug. 20, 2018-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other
View HTML
Toggle Summary Aerie Pharmaceuticals Reports Topline Result from Rhopressa® Mechanism of Action Study
Clinical confirmation of the effect of Rhopressa ® on trabecular meshwork outflow facility in patients with open-angle glaucoma or ocular hypertension DURHAM, N.C. --(BUSINESS WIRE)--Aug. 15, 2018-- Aerie Pharmaceuticals , Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the
View HTML
TOP